Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Kidney Injury I: Introduction01:22

Acute Kidney Injury I: Introduction

619
Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
619
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

940
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
940
Acute Kidney Injury VI: Nursing Management01:22

Acute Kidney Injury VI: Nursing Management

410
Acute Kidney Injury (AKI) results in an inability to maintain fluid, electrolyte, and acid-base balance. Effective nursing management is critical in improving patient outcomes and includes comprehensive patient assessment and targeted interventions.Comprehensive Patient AssessmentA detailed history collection is essential, focusing on any recent infections, nephrotoxic medication use, or chronic conditions such as hypertension and diabetes that may contribute to AKI. During the physical...
410
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

305
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
305
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

841
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
841
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

279
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
279

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Host hydraulics constrain mistletoe resistance to drought-induced embolism.

The New phytologist·2026
Same author

Exploring gut microbiota responses to low-dose thallium exposure via food chain transfer: insights from soil-plant-human systems.

Environmental geochemistry and health·2026
Same author

Distinct intraspecific trait variations in two moss species: Insights from a latitudinal investigation across 66 coastal islands.

Plant diversity·2026
Same author

Integrating chromatin accessibility and GWAS identifies RUNX3 and TRAF1 as susceptibility genes for rheumatoid arthritis.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026
Same author

Visible-Light-Mediated Three-Component Synthesis of Perfluoroalkylated Quinoline Derivatives via an Electron Donor-Acceptor Complex.

The Journal of organic chemistry·2026
Same author

[Expression of <i>GATA3</i> in Patients with Peripheral T-Cell Lymphoma and Its Clinical Significance].

Zhongguo shi yan xue ye xue za zhi·2026

Related Experiment Video

Updated: Jan 21, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

5.3K

Hepatopoietin Cn (HPPCn) Generates Protective Effects on Acute Liver Injury.

Na Li1, Feng-Jiao Liu1, Dan-Dan Li2

  • 1School of Pharmacy, Key Laboratory of Applied Pharmacology, Weifang Medical University, Wei Fang, China.

Frontiers in Pharmacology
|July 24, 2019
PubMed
Summary

Hepatopoietin Cn (HPPcn) protein protects liver cells from chemical damage by reducing apoptosis and promoting proliferation. This finding offers new therapeutic strategies for acute liver injury treatment.

Keywords:
acute liver injuryhepatopoietin Cnliver regenerationproliferationprotection

More Related Videos

Histological Analyses of Acute Alcoholic Liver Injury in Zebrafish
10:45

Histological Analyses of Acute Alcoholic Liver Injury in Zebrafish

Published on: May 25, 2017

15.1K
Inducing Acute Liver Injury in Rats via Carbon Tetrachloride CCl4 Exposure Through an Orogastric Tube
06:12

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride CCl4 Exposure Through an Orogastric Tube

Published on: April 28, 2020

12.0K

Related Experiment Videos

Last Updated: Jan 21, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

5.3K
Histological Analyses of Acute Alcoholic Liver Injury in Zebrafish
10:45

Histological Analyses of Acute Alcoholic Liver Injury in Zebrafish

Published on: May 25, 2017

15.1K
Inducing Acute Liver Injury in Rats via Carbon Tetrachloride CCl4 Exposure Through an Orogastric Tube
06:12

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride CCl4 Exposure Through an Orogastric Tube

Published on: April 28, 2020

12.0K

Area of Science:

  • Hepatology
  • Cell Biology
  • Toxicology

Background:

  • Acute liver injury (ALI) poses a significant health burden, necessitating novel therapeutic interventions.
  • Hepatopoietin Cn (HPPcn) is a protein with potential regenerative properties.
  • Understanding HPPcn's role in protecting hepatocytes from toxic insults is crucial for developing effective treatments.

Purpose of the Study:

  • To investigate the protective effects of recombinant human HPPcn (rhHPPCn) against chemically induced acute liver injury.
  • To elucidate the mechanisms underlying rhHPPCn's hepatoprotective actions, including its impact on cell survival, apoptosis, and proliferation.

Main Methods:

  • Hepatoma cells (SMMC7721) were treated with toxins (CCl4, ethanol, H2O2) and varying concentrations of rhHPPCn.
  • Cell viability (CCK-8 assay), apoptosis (flow cytometry), and proliferation markers (BrdU, PCNA via IHC) were assessed.
  • An in vivo mouse model of ALI induced by CCl4 was used, with rhHPPCn administration via tail vein injection, followed by serum enzyme analysis (GOT, GPT) and liver histopathology.

Main Results:

  • rhHPPCn significantly increased SMMC7721 cell survival and inhibited toxin-induced apoptosis.
  • rhHPPCn treatment reduced levels of liver injury markers (GOT, GPT, MDA, LDH) and increased antioxidant enzymes (GSH-PX, SOD) in vitro.
  • rhHPPCn promoted cell proliferation in a dose-dependent manner and significantly reduced serum GOT and GPT levels, alleviated liver tissue damage, and increased PCNA expression in vivo.

Conclusions:

  • rhHPPCn demonstrates significant hepatoprotective effects against chemical toxins both in vitro and in vivo.
  • The protective mechanism involves the inhibition of apoptosis and the promotion of hepatocyte proliferation.
  • rhHPPCn holds promise as a novel therapeutic agent for the clinical management of acute liver injury.